Pacer Advisors
TGTX icon

Pacer Advisors’s TG Therapeutics TGTX Stock Holding History

Pacer Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-11,863
Closed -$277K – 3728
2024
Q3 		$277K Buy
11,863
+9,946
+519% +$217K ﹤0.01% 1781
2024
Q2 		$34.1K Sell
1,917
-625
-25% -$9.97K ﹤0.01% 3312
2024
Q1 		$38.7K Buy
+2,542
New +$40.5K ﹤0.01% 3272
2021
Q2 		– Sell
-1,562
Closed -$75K – 1554
2021
Q1 		$75K Sell
1,562
-1,568
-50% -$75.3K ﹤0.01% 1346
2020
Q4 		$163K Sell
3,130
-2,988
-49% -$101K ﹤0.01% 1268
2020
Q3 		$164K Buy
+6,118
New +$141K ﹤0.01% 1206
2018
Q4 		– Sell
-10,626
Closed -$60K – 993
2018
Q3 		$60K Buy
+10,626
New +$121K ﹤0.01% 1133
2018
Q1 		– Sell
-3,425
Closed -$28K – 1127
2017
Q4 		$28K Buy
+3,425
New +$29.9K ﹤0.01% 1075

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Pacer Advisors's TGTX Position: Q4 2024 in Review

Pacer Advisors sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 11,863 shares — an estimated $277K sold.

Pacer Advisors first reported a position in TGTX in Q4 2017 and held it in 8 quarters. The position peaked at $277K in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Pacer Advisors reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Pacer Advisors sold 11,863 TG Therapeutics shares in Q4 2024, an estimated $277K.
  • Pacer Advisors first reported a position in TG Therapeutics in Q4 2017 and held it in 8 quarters.
  • Pacer Advisors's TG Therapeutics position peaked at $277K in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Pacer Advisors's 13F filing for Q4 2024, filed 22 Jan 2025.